Consortium for Immunotherapeutics against Emerging Viral Threats

针对新兴病毒威胁的免疫治疗联盟

基本信息

批准号：
10199909
负责人：
Erica Ollmann Saphire
金额：
$ 268.88万
依托单位：
LA JOLLA INSTITUTE FOR IMMUNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-27 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10199909
关键词：
2019-nCoV Address Affinity Antibodies Antibody Therapy Antibody-mediated protection Antigen-Antibody Complex Area Binding Biological Assay Blinded Characteristics Clinical Clinical Research Complement Complex Coronavirus Cryoelectron Microscopy Data Data Set Databases Engineering Ensure Epitopes FAIR principles Funding Geometry Half-Life Human Immunoglobulin G Immunotherapeutic agent In Vitro International Knowledge Maps Mechanics Mediating Membrane Myeloid Cells Participant Population Predisposition Proteins Race Research Project Grants Risk Sampling Serologic tests Side Site Speed Structure Surface Surveys System Therapeutic Therapeutic antibodies Time Transgenic Model United States National Institutes of Health Variant Viral clinical candidate experimental study mouse model neonatal Fc receptor next generation novel programs therapeutic candidate tool

项目摘要

ABSTRACT We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike protein contributed by a range of large and small companies and academic labs on multiple continents. CoVIC provides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assay conditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities and potencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. The currently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: binding and mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV- 2. The proposed supplement will provide support for critical components that are currently missing from CoVIC but which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offer durable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or risk of enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape. The resulting body of information will inform early and next-generation antibody therapies and will ensure that therapeutics are known which are responsive to emerging viral variants.

抽象的我们最近发起了冠状病毒免疫治疗联盟 (CoVIC)，这是一项国际努力对 SARS-CoV-2 Spike 的主要候选治疗抗体进行并行分析蛋白质由多个大洲的一系列大大小小的公司和学术实验室提供。冠状病毒IC 提供了在同一测定下对主要候选治疗药物进行并列分析的机会条件，以及实时协作组装有关活动和活动的更广泛、更深入的数据集抗 SARS-CoV-2 抗体的效力比任何单一发现工作单独组装的抗体的效力都要高。这目前资助的 CoVIC 研究主要集中在 IgG 治疗剂的 Fab 区域的特征上：结合和机械中和，并仅分析来自 SARS-CoV 的原始武汉参考株的尖峰 2. 拟议的补充将为 CoVIC 目前缺失的关键组件提供支持但这是加速安全、有效并提供抗体临床进展所必需的持久的保护。我们将确定治疗性抗体的 Fc 介导活性、可能性或风险临床候选物的增强程度，以及哪些表位和位点以及对诱变逃逸的易感性。由此产生的信息将为早期和下一代抗体疗法提供信息，并确保已知对新出现的病毒变体有反应的疗法。